Bilirubin and risk of ischemic heart disease in Korea: a two-sample Mendelian randomization study
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
whethOBJECTIVES: Bilirubin is an endogenous antioxidant that protects cells against oxidative stress. Increased plasma levels of bilirubin have been associated with a reduced risk of ischemic heart disease (IHD) in previous studies. Nonetheless, whether those associations reflect a true protective effect of bilirubin on IHD, rather than confounding or reverse causation, remains unknown. Therefore, we applied two-sample Mendelian randomization to evaluate the causal association between bilirubin levels and IHD risk in a Korean population. METHODS: A total of 5 genetic variants—TRPM8 (rs10490012), USP40 (rs12993249), ATG16L1 (rs2119503), SLCO1B1 (rs4149014), and SLCO1B3 (rs73233620)—were selected as genetic instruments for serum bilirubin levels using a community-based cohort, the Korean Genome and Epidemiology Study, comprising 33,598 subjects. We then evaluated their impact on IHD using the Korean Cancer Prevention Study-II cohort. RESULTS: Among the 5 instrumental variables that showed significant associations with serum bilirubin levels, rs12993249 (USP40) showed the most significant association (p<2.36×10-105). However, we found no significant association between serum bilirubin levels and IHD. Sensitivity analyses demonstrated a consistent association, suggesting that our observations were robust. CONCLUSIONS: Using two-sample Mendelian randomization, we found no association between serum bilirubin levels and IHD. Further studies that confirm the observed interactions among other ethnicities are warranted.
Abstract
whethOBJECTIVES: Bilirubin is an endogenous antioxidant that protects cells against oxidative stress. Increased plasma levels of bilirubin have been associated with a reduced risk of ischemic heart disease (IHD) in previous studies. Nonetheless, whether those associations reflect a true protective effect of bilirubin on IHD, rather than confounding or reverse causation, remains unknown. Therefore, we applied two-sample Mendelian randomization to evaluate the causal association between bilirubin levels and IHD risk in a Korean population. METHODS: A total of 5 genetic variants—TRPM8 (rs10490012), USP40 (rs12993249), ATG16L1 (rs2119503), SLCO1B1 (rs4149014), and SLCO1B3 (rs73233620)—were selected as genetic instruments for serum bilirubin levels using a community-based cohort, the Korean Genome and Epidemiology Study, comprising 33,598 subjects. We then evaluated their impact on IHD using the Korean Cancer Prevention Study-II cohort. RESULTS: Among the 5 instrumental variables that showed significant associations with serum bilirubin levels, rs12993249 (USP40) showed the most significant association (p<2.36×10-105). However, we found no significant association between serum bilirubin levels and IHD. Sensitivity analyses demonstrated a consistent association, suggesting that our observations were robust. CONCLUSIONS: Using two-sample Mendelian randomization, we found no association between serum bilirubin levels and IHD. Further studies that confirm the observed interactions among other ethnicities are warranted.
참고문헌 (19)
- Stocker R, "Antioxidant activities of bile pigments", Antioxid Redox Signal, 6, pp.841~849 (2004)
- Wu ML, "Heme oxygenase-1 in inflammation and cardiovascular disease", Am J Cardiovasc Dis, 1, pp.150~158 (2011)
- Libby P, "Inflammation and atherosclerosis", Circulation, 105, pp.1135~1143 (2002)
- Kunutsor SK, "Circulating total bilirubin and risk of incident cardiovascular disease in the general population", Arterioscler Thromb Vasc Biol, 35, pp.716~724 (2015)
- Lin JP, "Association between the UGT1A1*28 allele, bilirubin levels, and coronary heart disease in the Framingham Heart Study", Circulation, 114, pp.1476~1481 (2006)
- Kronenberg F, "Association of bilirubin with cardiovascular outcomes : more hype than substance?", Circ Cardiovasc Genet, 3, pp.308~310 (2010)
- Stender S, "Genetically elevated bilirubin and risk of ischaemic heart disease : three Mendelian randomization studies and a meta-analysis", J Intern Med, 273, pp.59~68 (2013)
- Kim Y, "Cohort profile : the Korean Genome and Epidemiology Study(KoGES)Consortium", Int J Epidemiol, 46, pp.1350~ (2017)
- Jee YH, "Cohort profile : the Korean Cancer Prevention Study-II(KCPS-II)Biobank", Int J Epidemiol, 47, pp.385f~386f (2018)
- Davies NM, "Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians", BMJ, 362, pp.k601~ (2018)
- Hartwig FP, "Two-sample Mendelian randomization : avoiding the downsides of a powerful, widely applicable but potentially fallible technique", Int J Epidemiol, 45, pp.1717~1726 (2016)
- Schooling CM, "Alanine transaminase has opposite associations with death from diabetes and ischemic heart disease in NHANES III", Ann Epidemiol, 22, pp.789~798 (2012)
- Temme EH, "Serum bilirubin and 10-year mortality risk in a Belgian population", Cancer Causes Control, 12, pp.887~894 (2001)
- Lee SJ, "Bilirubin and stroke risk using a Mendelian randomization design", Stroke, 48, pp.1154~1160 (2017)
- Kang TW, "Genome-wide association of serum bilirubin levels in Korean population", Hum Mol Genet, 19, pp.3672~3678 (2010)
- Davey Smith G, "Mendelian randomization: genetic anchors for causal inference in epidemiological studies", Hum Mol Genet, 23, pp.R89~R98 (2014)
- Lawlor DA, "Commentary : two-sample Mendelian randomization : opportunities and challenges", Int J Epidemiol, 45, pp.908~915 (2016)
- Taylor AE, "Mendelian randomization in health research : using appropriate genetic variants and avoiding biased estimates", Econ Hum Biol, 13, pp.99~106 (2014)
- Rothman KJ, "Causation and causal inference in epidemiology", Am J Public Health, 95(Suppl 1), pp.S144~S150 (2005)